Table of Contents

Acknowledgments
Chapter 1 Evidence, Politics, and Medical Care Technology
Chapter 2 Evolving Public- and Private-Payer Approaches to Evidence and Health Technology Assessment
Chapter 3 Mammography Screening: Vested Interests and Polarization
Chapter 4 When Medicare Said No for Amyloid PET Imaging
Chapter 5 Placing a Value on Cure: Lessons from the New Generation of Hepatitis C Drugs
Chapter 6 Avastin and the Politics of Accelerated Approval
Chapter 7 The Path to the Clinic for Stem Cell and Other Regenerative Medicine Interventions
Chapter 8 Conclusion: The 21st Century Cures Act and the Future of Health Technology Assessment
Notes
Bibliography
Index

Promotional Information

This book analyzes policy fights about what counts as good evidence of safety and effectiveness when it comes to new health care technologies in the United States and what political decisions mean for patients and doctors.

About the Author

Karen J. Maschke is research scholar at the Hastings Center with expertise on the ethical, legal, and policy issues associated with new biomedical technologies. She is editor of IRB: Ethics & Human Research.

Michael K. Gusmano is associate professor of health policy at Rutgers University and research scholar at the Hastings Center with expertise on the politics of health reform, comparative politics, and health technology assessment.